Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-04-15
2008-10-07
Mondesi, Robert B. (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07432238
ABSTRACT:
A human Kunitz-type inhibitor polypeptide with enhanced antifibrinolytic activity, methods of making, and methods of use. The novel polypeptide is structurally similar to the KD1 domain of human tissue factor pathway inhibitor-2 (TFPI-2).
REFERENCES:
patent: 4595674 (1986-06-01), Tschesche et al.
patent: 4894436 (1990-01-01), Auerswald et al.
patent: 5032573 (1991-07-01), Auerswald et al.
patent: 5455338 (1995-10-01), Sprecher et al.
patent: 5728674 (1998-03-01), Sprecher et al.
patent: 5914315 (1999-06-01), Sprecher et al.
patent: 5981471 (1999-11-01), Papathanassiu et al.
patent: 6656746 (2003-12-01), Sprecher et al.
patent: 2004/0253686 (2004-12-01), Sprecher et al.
patent: 2005/0004021 (2005-01-01), Sprecher et al.
GenCore version 6.2, Biocceleration Ltd., OM protein—protein search, using sw model Run on:Mar. 7, 2007, pp. 1-2.□□
Bowie, et al., Deciphering the message in the protein sequences: Tolerance to amino acid substitutions (1990) Science, vol. 247, pp. 1306-1310.
Rudinger, Peptide Hormones, University Park Press, 1976, Baltimore, MD., pp. 1-7.
Xu et al., “Tissue factor pathway inhibitor-2 is upregulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells”Arteriosclerosis, Thrombosis, and Vascular Biology, 2006; 26:2819-2825; originally published online Oct. 5, 2006.
U.S. Appl. No. 60/754,913, filed Dec. 29, 2005, Kisiel et al.
U.S. Appl. No. 60/754,731, filed Dec. 29, 2005, Bajaj.
Abdulkadir et al., “Tissue factor expression and angiogenesis in human prostate carcinoma”,Hum Pathol.Apr. 2000;31(4):443-447.
Andre et al., “Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa”,Int. J. Cancer, Apr. 15, 2000;86(2):174-181.
Aprotinin dosing regimen, Physician's Desk Reference, Monvale, NJ, 2004; title page and p. 864.
Bajaj et al., “Structure and biology of tissue factor pathway inhibitor”,Thromb. Haemost., Oct. 2001; 86(4):959-972.
Bajaj, “Molecular Recognition in Factor VIIa Induced Coagulation”, Grant Abstract, Grant No. 1R01HL070369-01 [online]. National Institute of Health, Apr. 1, 2002 to Mar. 31, 2006 [retrieved on Aug. 24, 2006]. Retrieved from the Internet:<URL:http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6485087&p—grant—num=1R01HL070369-01&p—query=&ticket=23890738&p—audit—session—id=118596397&p—keywords=>; 2 pages.
Bajaj, “Molecular Recognition in Factor VIIa Induced Coagulation”, Grant Abstract, Grant No. 5R01HL070369-02 [online]. National Institute of Health, Apr. 1, 2002 to Oct. 31, 2003 [retrieved on Aug. 24, 2006]. Retrieved from the Internet:<URL:http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6626039&p—grant—num=5R01HL070369-02&p—query=&ticket=23890738&p—audit—session—id=118596397&p—keywords=>; 2 pages.
Bajaj, “Molecular Recognition in Factor VIIa Induced Coagulation”, Grant Abstract, Grant No. 7R01HL070369-03 [online]. National Institute of Health, Apr. 1, 2002 to Mar. 31, 2006 [retrieved on Aug. 24, 2006]. Retrieved from the Internet:<URL:http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6852031&p—grant—num=7R01HL070369-03&p—query=&ticket=23890738&p—audit—session—id=118596397&p—keywords=>; 2 pages.
Bajaj, “Molecular Recognition in Factor VIIa Induced Coagulation”, Grant Abstract, Grant No. 5R01HL070369-04 [online]. National Institute of Health, Apr. 1, 2002 to Mar. 31, 2006 [retrieved on Aug. 24, 2006]. Retrieved from the Internet:<URL:http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6853536&p—grant—num=5R01HL070369-04&p—query=&ticket=23890738&p—audit—session—id=118596397&p—keywords=>; 2 pages.
Bajaj, “Molecular Recognition in Factor VIIa Induced Coagulation”, Grant Abstract, Grant No. 5R01HL070369-05 [online]. National Institute of Health, Apr. 1, 2002 to Mar. 31, 2007 [retrieved on Aug. 24, 2006]. Retrieved from the Internet:<URL:http://crisp.cit.nih.gov/crisp/CRISP—LIB.getdoc?textkey=6891020&p—grant—num=5R01HL070369-05&p—query=&ticket=2380738&p—audit—session—id=118596397&p—keywords=>; 2 pages.
Banner et al., “The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor”,Nature, Mar. 7, 1996;380(6569):41-46.
Beierlein et al., “Forty years of clinical aprotinin use: a review of 124 hypersensitivity reactions”Ann. Thorac. Surg., Feb. 2005;79(2):741-748.
Bernstein et al., “Comparison of techniques for the successful detection of BRCA1 mutations in fixed paraffin-embedded tissue”,Cancer Epid. Biomark. Prev., Sep. 2002;11(9):809-814.
Bieth, “In vivo significance of kinetic constants of protein proteinase inhibitors”,Biochem. Med., Dec. 1984;32(3):387-397.
Bizik et al., “Plasminogen activation by t-PA on the surface of human melanoma cells in the presence of alpha 2-macroglobulin secretion”,Cell Regul., Nov. 1990;1(12):895-905.
Bode et al., Structural basis of the endoproteinase-protein inhibitor interaction,Biochim. Biophys. Acta, Mar. 7, 2000;1477(1-2):241-252.
Bodner et al., “CD4 dependence of gp120IIIB-CXCR4 interaction is cell-type specific”,J. Neuroimmunol., Jul. 2003;140(1-2):1-12.
Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding”,Anal. Biochem., May 7, 1976;72:248-254.
Broze et al., “Regulation of coagulation by a multivalent Kunitz-type inhibitor”,Biochemistry, Aug. 21, 1990;29(33):7539-7546.
Burgering et al., “The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa”,J. Mol. Biol., Jun. 13, 1997;269(3):395-407.
Castellino et al., “Structure and function of the plasminogen/plasmin system”Thromb. Haemost., Apr. 2005;93(4):647-654.
Castro et al., “Alanine point-mutations in the reactive region of bovine pancreatic trypsin inhibitor: effects on the kinetics and thermodynamics of binding to beta-trypsin and alpha-chymotrypsin”,Biochemistry, Sep. 3, 1996; 35(35):11435-11446.
Chand et al., “The effect of human tissue factor pathway inhibitor-2 on the growth and metastasis of fibrosarcoma tumors in athymic mice”,Blood, Feb. 1, 2004;103(3):1069-1077. Epub Oct. 2, 2003.
Chand et al., “Structure-Function Analysis of the Reactive Site in the First Kunitz-type Domain of Human Tissue Factor Pathway Inhibitor-2”,J. Biol. Chem., Apr. 23, 2004;279(17):17500-17507. Epub Feb. 16, 2004. Erratum in: J. Biol. Chem. 2004; 279(23):24906.
Chau et al., “Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1”,Mol. Cell, Jul. 2000;6(1):31-40.
Choong et al., “Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis”Clin. Orthop. Relat. Res., Oct. 2003(415 Suppl):S46-S58.
Cohen et al., “Nonchromosomal antibiotic resistance in bacteria: genetic transformation ofEscherichia coliby R-factor DNA”,Proc. Natl. Acad. Sci. USA, Aug. 1972;69(8):2110-2114.
Coligan et al., Unit 9,Current Protocols in Immunology, Wiley Interscience, Hoboken, NJ, Copyright 1991-2005. Cover page, copyright page and table of contents for Unit 9, 4 pgs. total.
Coligan et al., “Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters”, Section 2.4.1 and 2.5.1-2.6.7,Current Protocols in Immunology, Hoboken, NJ, Copyright 1991-2005. Cover page, copyright page, tabl
Chand Hitendra S.
Kisiel Walter
Mondesi Robert B.
Mueting Raasch & Gebhardt, P.A.
STC.UNM
LandOfFree
Human Kunitz-type inhibitor with enhanced antifibrinolytic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human Kunitz-type inhibitor with enhanced antifibrinolytic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human Kunitz-type inhibitor with enhanced antifibrinolytic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4015132